Difference between revisions of "Warm autoimmune hemolytic anemia"
Jump to navigation
Jump to search
m (Jwarner moved page Autoimmune hemolytic anemia to Warm autoimmune hemolytic anemia: More accurate) |
|||
Line 6: | Line 6: | ||
|- | |- | ||
|} | |} | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Line 19: | Line 18: | ||
=All lines of therapy= | =All lines of therapy= | ||
− | + | ||
− | [[Category: | + | ==Prednisolone monotherapy {{#subobject:5f27f2|Regimen=1}}== |
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | |||
+ | ===Regimen {{#subobject:d3c7eb|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 25%" |Study | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 25%" |Comparator | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12541 Birgens et al. 2013] | ||
+ | | style="background-color:#1a9851" |Phase III (C) | ||
+ | |[[#Prednisolone_.26_Rituximab|Prednisolone & Rituximab]] | ||
+ | | style="background-color:#fc8d59" |Seems to have inferior RFS | ||
+ | |- | ||
+ | |} | ||
+ | ====Immunosuppressive therapy==== | ||
+ | *[[Prednisolone (Millipred)]] | ||
+ | |||
+ | ===References=== | ||
+ | # Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. Epub 2013 Aug 24. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12541 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23981017 PubMed] | ||
+ | |||
+ | ==Prednisolone & Rituximab {{#subobject:598gf2|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | |||
+ | ===Regimen {{#subobject:a7c7eb|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 25%" |Study | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 25%" |Comparator | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
+ | |- | ||
+ | |[https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12541 Birgens et al. 2013] | ||
+ | | style="background-color:#1a9851" |Phase III (E) | ||
+ | |[[#Prednisolone_monotherapy|Prednisolone]] | ||
+ | | style="background-color:#91cf60" |Seems to have superior RFS | ||
+ | |- | ||
+ | |} | ||
+ | ====Immunosuppressive therapy==== | ||
+ | *[[Prednisolone (Millipred)]] | ||
+ | *[[Rituximab (Rituxan)]] | ||
+ | ===References=== | ||
+ | # Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. Epub 2013 Aug 24. [https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.12541 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23981017 PubMed] | ||
+ | |||
+ | [[Category:Warm autoimmune hemolytic anemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Autoimmune hematologic conditions]] | [[Category:Autoimmune hematologic conditions]] | ||
[[Category:Hemolytic process]] | [[Category:Hemolytic process]] |
Revision as of 14:09, 1 October 2019
Section editor | |
---|---|
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
4 regimens on this page
3 variants on this page
|
Guidelines
British Society for Haematology
- 2017: Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia PubMed
- 2016: The diagnosis and management of primary autoimmune haemolytic anaemia PubMed
All lines of therapy
Prednisolone monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Birgens et al. 2013 | Phase III (C) | Prednisolone & Rituximab | Seems to have inferior RFS |
Immunosuppressive therapy
References
- Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. Epub 2013 Aug 24. link to original article PubMed
Prednisolone & Rituximab
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Birgens et al. 2013 | Phase III (E) | Prednisolone | Seems to have superior RFS |
Immunosuppressive therapy
References
- Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, Larsen H, Mourits-Andersen T, Plesner T, Rønnov-Jessen D, Vestergaard H, Klausen TW, Schöllkopf C. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. Epub 2013 Aug 24. link to original article PubMed